Ifinatamab Deruxtecan Granted Priority Review in the U.S. for Adult Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer who Experienced Disease Progression on or After Platinum-Based Chemotherapy

Key Takeaway: Ifinatamab Deruxtecan has been granted priority review by the U.S. FDA for adult patients with previously treated extensive-stage small cell lung cancer. This designation is specifically for patients who have experienced disease progression on or after platinum-based chemotherapy. The priority review indicates the FDA's intent to expedite the evaluation process for this treatment.